3
Participants
Start Date
May 5, 2021
Primary Completion Date
August 1, 2021
Study Completion Date
August 1, 2021
Mifepristone
Mifepristone is a selective antagonist of the progesterone receptor at low doses and blocks the glucocorticoid receptor (GR-II) at higher doses. Mifepristone has high affinity for the GR-II receptor but little affinity for the GR-I (MR, mineralocorticoid) receptor.
University of Michigan, Ann Arbor
Collaborators (1)
Corcept Therapeutics
INDUSTRY
Tobias Else
OTHER